Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NORTH CHICAGO, Ill., June 23, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) in combination with...

IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM)

NORTH CHICAGO, Ill., June 22, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX® prescribing information for the...

FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is AbbVie (ABBV) Stock Undervalued Right Now?

Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.

Alpine Skyrockets on License Deal With AbbVie for ALPN-101

AstraZeneca

Bristol-Myers

Eli Lilly

Here we highlight four large drugmakers that can prove to be safe bets amid the coronavirus crisis.

Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay

Broadcom

Booking Hlds

Cheesecake Factory

Alphabet

Microsoft

Take-Two Interactive Software

Another buying opportunity could be in the making due to COVID-19. I believe it's important to be prepared and made a shortlist of companies to buy.

7 Stocks I'm Buying During A Correction

Essex Property Trust

Altria

AT&T

Walgreens

A second wave has become more likely, with cases in states such as California and Texas rising to new record levels over the last couple of days.

Prepare For A Second Wave With These 5 Undervalued Low-Risk Dividend Aristocrats

IRVINE, Calif., June 15, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the FDA approval of JUVÉDERM® VOLUMA™ XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21.1 As the category leader, the...

FDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region

3 Blue Chip Stocks With Up To 8.6% Dividend Yield

NORTH CHICAGO, Ill., June 13, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the positive results from the VIALE-A (M15-656) trial, which demonstrated that previously-untreated patients with acute myeloid leukemia (AML) who...

VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients

NORTH CHICAGO, Ill., June 12, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited "mini-tender" offer, dated June 1, 2020, to purchase up to 1,500,000 shares of AbbVie common stock at $88.05 per share....

AbbVie Recommends Shareholders Reject TRC Capital's "Mini-Tender" Offer

NORTH CHICAGO, Ill., June 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior rates of skin clearance for SKYRIZI® (risankizumab-rzaa) to COSENTYX® (secukinumab) at...

AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks

American States Water

Axcella Health Inc

B&G Foods

Clorox

An alarming rise in the number of coronavirus cases results in volatility in the market and raises the appeal of defensive stocks

5 Defensive Stocks to Buy as Coronavirus Cases Rise Again

MEI Pharma

Ollie's Bargain Outlet Hlds

Vistra Energy

Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.

Go Defensive to Beat Market Turbulence With These 4 Stocks

AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Further, AbbVie is collaborating on a coronavirus drug.

AbbVie Jumped Into The Coronavirus Drug Hunt — Is AbbVie Stock A Buy?

Eagle Bancorp Montana

H&R Block

Mackinac Financial

Virtu Financial

Low-beta dividend paying names may be the best way to go in a volatile market.

6 Defensive Stocks to Beat the Volatility

Genmab - ADR

AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.

AbbVie Inks Deal With Genmab, Announces ADC Candidate Data

AbbVie scores in the courtroom, in the clinic, and in a collaboration deal.

3 Wins for AbbVie in 3 Days Provide 3 More Good Reasons to Buy the Pharma Stock

That's the finding of a clinical trial of ABBV-3373, a new type of antibody-drug conjugate.

AbbVie's Humira on Steroids (Literally) Treats Rheumatoid Arthritis Better Than the Original

The partners will develop and hopefully commercialize up to seven new cancer drugs.

AbbVie Signs $3.9 Billion Oncology Deal with Genmab

Shares of Genmab popped Wednesday after the biotech inked a deal with pharma giant AbbVie to develop cancer treatments. The deal is potentially worth billions in milestone payments.

Genmab Hits Pay Dirt On A Potential $3 Billion Deal With AbbVie

Fortinet

NVIDIA

Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.

ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks

NORTH CHICAGO, Ill., June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from a Phase 2a study of ABBV-3373, an investigational anti-tumor necrosis factor (TNF) Glucocorticoid Receptor Modulator (GRM) steroid...

Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis

Shares of Genmab A/S GMAB, +1.33% rose 4.5% in premarket trading Wednesday, after the Denmark-based biotechnology company announced a collaboration agreement with AbbVie Inc.

Genmab's stock surges after drug development deal with AbbView valued at up to nearly $4 billion

NORTH CHICAGO, Illinois and COPENHAGEN, Denmark, June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage...

News for AbbVie Stock (ABBV)